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Basal cell carcinoma, the most frequent skin cancer
in humans, is often linked to chronic sun exposure.
In psoralen and ultraviolet A-treated psoriatic
patients, basal cell carcinomas may occur even more
frequently; however, the exact etiology and mechan-
isms of tumorigenesis in psoriatic patients are
unclear because psoralen and ultraviolet A is not
only a carcinogen but also an immunosuppressor
and because psoralen and ultraviolet A-treated psor-
iatic patients often have other (co)carcinogenic risk
factors (e.g, therapeutic exposure to ultraviolet B,
X-ray radiation, arsenic, tar, and/or chemo-
therapeutic agents such as methotrexate). In this
study, we analyzed the DNA of 13 basal cell carcino-
mas from ®ve psoralen and ultraviolet A-treated
psoriatic patients for mutations of the p53 tumor
suppressor gene. DNA sequencing revealed a total of
11 mis-sense, two non-sense, and four silent muta-
tions in seven of the 13 basal cell carcinomas (54%).
Of the 13 total mis-sense or non-sense mutations, 12
(92%) occurred at dipyrimidine sites and nine (69%)
were of the ultraviolet ®ngerprint type (eight C®T
transitions and one CC®TT transition). Three of the
C®T transitions occurred at dipyrimidine sites
opposite a 5¢-TpG sequence (a potential psoralen-
binding site and target for psoralen and ultraviolet A
mutagenesis). Thus, whether these mutations were
induced by ultraviolet or psoralen and ultraviolet A
was not clear. In addition, two other mutations
(15%) occurred at 5¢-TpG sites, one (8%) occurred at
a 5¢-TpA site (the most frequent site of psoralen
binding and mutagenesis in cell and murine studies),
and one (8%) involved a G®T transversion. These
results suggest that (i) the major initiator of p53
mutations in basal cell carcinoma in psoralen and
ultraviolet A-treated psoriasis patients is environ-
mental and/or therapeutic ultraviolet(B) exposure,
and that (ii) psoralen and ultraviolet A itself causes
only a smaller portion of p53 mutations in psoralen
and ultraviolet A-associated basal cell carcinomas.
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P
soriasis patients exposed to high cumulative doses of
psoralen and ultraviolet A (PUVA) are at increased risk
for cutaneous squamous cell carcinoma (SCC) (for
review see Stern et al, 1998), and possibly for malignant
melanoma (Stern et al, 1997). In addition PUVA-treated
patients may be at increased risk for basal cell carcinoma (BCC)
(Bruynzeel et al, 1991; McKenna et al, 1996). For instance, in the
most recent follow-up report of the U.S. multicenter PUVA study
there was a persistent strong UVA dose-dependent increase in the
risk of SCC (by a factor of 17.6), but only a moderate increase in
that of BCC (by a factor of 4.1) after adjustment for age, sex, and
residence (Stern et al, 1998). Moreover, after adjustment for all
other signi®cantly associated risk factors (UVB radiation, tar,
X-rays, and grenz rays), the risk of BCC was even less on sites other
than the (sun-exposed) head and neck. At present, the exact reasons
for the increased risk for skin cancer in PUVA-treated patients are
not completely known because PUVA is not only mutagenic
(Gunther et al, 1995) and carcinogenic (Kripke et al, 1982) but also
immunosuppressive (Strauss et al, 1980; Kripke et al, 1982). The
fact that many PUVA-treated psoriasis patients harbor additional
potentially carcinogenic risk factors, such as exposure to UVB,
X-rays, tar, methotrexate, and/or arsenic (Maier et al, 1996), makes
the situation even more complex.
Recently, two groups of investigators (Nataraj et al, 1997; Wang
et al, 1997) performed molecular sequence analysis studies on the
p53 tumor suppressor gene in PUVA-associated SCC in order to
link mutation spectra to risk factors and identify the possible causes
of that tumor type in long-term PUVA-treated subjects.
Importantly, in both studies a large portion of the detected p53
mutations (32% and 40%, respectively) were at dipyrimidine sites
and of the UV ®ngerprint type (i.e, C®T and CC®TT
transitions), suggesting that DNA damage caused by UV(B)
exposure may be a signi®cant factor in the formation of SCC in
PUVA-treated patients. In the study by Nataraj et al (1997),
however, approximately half of the mutations were detected at
5¢-TpG sites, which are possible psoralen-binding sites and targets
for PUVA mutagenesis. Indeed, comparison of the mutation
Manuscript received November 13, 2000; revised February 28, 2001;
accepted for publication March 28, 2001.
Reprint requests to: Dr. Peter Wolf, Department of Dermatology,
University of Graz, Auenbrugger Platz 8, 8036 Graz, Austria.
Email: peter.wolf@kfunigraz.ac.at
Abbreviations: MOP, methoxypsoralen; BCC, basal cell carcinoma;
SSCP, single-strand conformation polymorphism; SCC, squamous cell
carcinoma.
0022-202X/01/$15.00 ´ Copyright # 2001 by The Society for Investigative Dermatology, Inc.
365
spectra of SCC from PUVA-treated patients vs the general
population revealed that signi®cantly more PUVA-type mutations
(de®ned as base changes occurring at 5¢-TpA, 5¢-TpG sites, and 5¢-
TpT sites) occurred in the former (64%) than in the latter (22%).
Although it had previously been reported that repeated A±T
sequences are hot spots for the photochemical reactions of 8-
methoxypsoralen (8-MOP) with DNA and 5¢-TpA sequences are
the preferential sites for psoralen monoadduct or interstrand cross-
link formation and subsequent carcinogenic events (Sage et al,
1993), the more recent work of Nataraj et al (1997) indicated that
PUVA exposure may directly initiate a substantial proportion of
skin cancers by causing p53 mutations at psoralen-binding 5¢-TpG
sites.
To investigate the potential role of PUVA in BCC formation in
psoriasis, we analyzed the p53 gene (exons 4±9) in BCC from
PUVA-treated psoriasis patients by polymerase chain reaction
(PCR) ±single-strand con®rmation polymorphism (SSCP) analysis
and DNA sequencing. The majority of p53 mutations we detected
in the BCC occurred at dipyrimidine sites and were of the UV
®ngerprint type; however, a smaller portion of mutations were at
5¢-TpG sites. This suggests that even though the major factor in
inducing p53 mutations (and possibly BCC tumorigenesis) in
PUVA-treated psoriasis patients seems to be therapeutic and/or
environmental UV(B) exposure, PUVA itself also directly causes
some of those p53 mutations.
MATERIALS AND METHODS
Patients and BCC samples Material of 13 BCC was available from
®ve psoriasis patients (A±E) who had a history of PUVA treatment. The
exact patients' demographics, risk factors, PUVA data, and tumor
characteristics are given in Table I.
DNA extraction For DNA extraction paraf®n-embedded tumor
samples were dissected to eliminate normal tissue adjacent to and in the
tumors to reduce the portion of nontumor cells in the samples. Brie¯y,
7±10 mm tissue sections were deparaf®nized with xylene (10 min) and
ethanol (10 min), air dried, and then damped into deionized water. The
dissected cells were then suspended in 50 ml of a solution containing
0.1 M Tris±HCl, pH 8.0, and 1 mg per ml proteinase K; incubated in a
water bath at 55°C overnight; and then boiled for 10 min. The
preparation was stored at ±20°C until used.
PCR±SSCP analysis DNA from exons 4±9 of the p53 gene was
ampli®ed using the primer sequences as listed in Table II. Primers with
slight modi®cations were used to amplify exons 4 and 5 (Brash et al,
1991) and exons 6±9 (Wang et al, 1997). Four microliters of each lysate
was used as the template in a 50 ml solution containing 10 mM Tris±
HCl pH 8.3, 50 mM KCl, 1.5 mM deoxyribonucleoside triphosphate at
100 mM each, upstream and downstream primers 10 pM each, and
2.5 U AmpliTag Gold (Perkin Elmer, Vienna, Austria). PCR assays were
run for 40 cycles of ampli®cation as follows: denaturation at 94°C for
45 s, annealing at 60°C for 30 s, and extension at 72°C for 30 s. Before
the ®rst cycle, tubes were incubated for 12 min at 94°C, after the last
cycle, for 7 min at 72°C. To avoid potential contamination of PCR and
to rule out PCR-generated mutations, every PCR reaction included
blank samples lacking DNA templates and other samples containing
human placental DNA. After ampli®cation, 50 ml of the PCR products
was fractionated by electrophoresis in 2.5% MetaPhor agarose gel (FMC
Bioproducts, Rockland, ME). Ampli®ed and puri®ed fragments were cut
out of the gel and extracted using a commercially available gel extraction
kit (Qiagen, Valencia, CA).
For SSCP, 0.5 ml (30 ng) ampli®ed and puri®ed DNA, 2.5 ml sample
buffer, and 3 ml denaturing solution were denaturated at 95°C for
10 min and thereafter placed on ice. Samples were loaded on to
mutation detection enhancement gels (Gene Gel Excel 12.5/24,
Amersham Pharmacia Biotech, Vienna, Austria). The gels were then run
for 95 min at 10°C (exons 7±9), 15°C (exon 6), and 20°C (exons 4 and
5). Running conditions were as follows: 600 V, 25 mA, and 15 W.
Once run, gels were stained using a DNA Silver Staining Kit (Amersham
Pharmacia Biotech). At least two independent PCR±SSCP analyses were
carried out per tumor sample.
Nucleotide sequencing All ampli®ed and puri®ed samples were: (i)
sequenced using 3.2 pM primer, 30 ng DNA, and sequencing reagents
(Cycle Sequencing Ready Reaction; Perkin Elmer, Foster City, CA); (ii)
precipitated; and (iii) separated in an ABI Prism 310 system (Perkin
Elmer). Both DNA strands were sequenced, and mutations on one strand
were always con®rmed on the opposite strand. Sequence analysis was
done on a Power Macintosh G3 (Apple Computer, Cupertino, CA)
using Sequence Analysis Software (Perkin Elmer).
Statistical analysis Differences in the number of mutations types
between different groups of subjects were analyzed for statistical
signi®cance using Fisher's exact test in the StatView statistical analysis
Table I. Patients' demographics, risk factors, PUVA data, and tumor characteristics
Subject Sexa Skin
phototypeb
Age at ®rst
PUVA
treatment
(years)
Total no.
of PUVA
treatments
Cumulative
UVA dose
(J per cm2)
Psoralen UVB
therapy
Non-PUVA
treatment
risk factors
Total tumors
BCC
of
study
Location
of
BCC
BCC
appearance
after ®rst
PUVA
treatment
(months)
A F III 43 60 310 8/5-MOP Yes Tar, X-rays,
methotrexate
7 BCC A1
A2
A3
A4
Scalp
Temple
Retroauricular
Retroauricular
129
220
220
189
B F N. A. 74 63 183 8-MOP Yes None 2 BCC, 7 SCC B1
B2
Retroauricular
Neck
1
119
C M III 47 813 4352 8-MOP Yes Arsenic, tar 1 BCC, 3 SCC C1 Retroauricular 160
D F III 59 134 776 8-MOP Yes None 3 BCC D1 Temple 154
E F III 50 452 1682 8/5-MOP Yes Arsenic, tar 5 BCC, 3 SCC E1
E2
E3
E4
E5
Temple
Nose
Scalp
Scalp
Scalp
182
241
228
186
181
Mean, 55
Range,
43±74
Mean, 304
Range,
60±813
Mean, 1460
Range,
310±4352
Mean, 170
Range,
1±241
aF, female; M, male.
bSkin phototype according to Fitzpatrick classi®cation.
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program version 5.0.1 (SAS Institute, Cary, NC). p < 0.05 was
considered signi®cant.
RESULTS
Both UV- and PUVA-type p53 mutations are present in
BCC from PUVA-treated patients A total of 13 BCC were
obtained from ®ve PUVA-treated psoriasis patients and analyzed
for p53 mutations by PCR±SSCP analysis and sequencing of exons
4±9. Sequencing revealed a total of 17 mutations (11 mis-sense,
two non-sense, and four silent mutations) in seven of 13 BCC
(54%) (Table III). Mutations of the UV type [CC®TT transition
(Fig 1A) and C®T transition (Fig 1C) at dipyrimidine sites] and
the PUVA type (T®C transition at a 5¢-TpA site) (Fig 1B) were
seen. Of the 13 mis-sense or non-sense mutations, 12 (92%) were at
dipyrimidine sites and nine (69%) were of the UV type (eight
C®T transitions and one CC®TT transition). Three of the C®T
transitions were at dipyrimidine sites opposite a 5¢-TpG sequence (a
potential psoralen-binding site) (A1, codon 94; A3, codon 67; and
D1, codon 317) (Table III). As this left the origin of these
mutations (UV or PUVA) ambiguous, they were considered
separately (Fig 2). In addition, two other mutations (15%) occurred
at 5¢-TpG sites (including one at a dipyrimidine and one at a
nondipyrimidine site), one mutation (8%) at a 5¢-TpA site (all of
potential PUVA origin), and one involved a (G:C®T:A)
transversion (8%). In addition, a BCC from patient C (tumor
C1) showed a G®C transversion in exon 4 of codon 72, a known
p53 polymorphism (Olschwang et al, 1991). Two tumors (A1 and
A3) had multiple mis-sense mutations (most of them of UV type) at
exons 4 and 5, respectively (Table III). In support of a previous
study (Nataraj et al, 1997), the greater intensity of wild-type vs
shifted (i.e, mutant) bands in the PCR±SSCP analysis (data not
shown) suggested that: (i) in most cases only one p53 allele was
mutated and the other was wild-type; (ii) only a portion of tumor
cells harbored mutations; and/or (iii) contaminating normal cells
were present in the tumor samples. Importantly, this is also
supported by the observation that most of our electropherograms
simultaneously showed wild-type and mutated DNA sequences
(Fig 1), consistent with the SSCP results. Taken together, these
®ndings suggested that there was no loss of heterozygosity at the
p53 gene of the BCC. Importantly, however, all p53 mutations
detected were somatic because they were not present in normal
tissue samples from the patients.
BCC from PUVA-treated patients have a similar incidence
of UV-type mutations but a higher proportion of PUVA-
type mutations than BCC from the general
population Data on the type and number of p53 mutations in
BCC from non-PUVA-treated subjects of the general population
were gathered from several previous studies (Rady et al, 1992;
Moles et al, 1993; Sato et al, 1993; Ziegler et al, 1993; Kanjial et al,
1995; Gailani et al, 1996; D'Errico et al, 1997; Ponten et al, 1997),
pooled, and compared with the data on the mutations found in
BCC from PUVA-treated patients (Fig 2). The total percentage of
mis-sense or non-sense UV ®ngerprint mutations at dipyrimidine
sites (i.e, C®T and CC®TT transitions) was 69% (nine of 13) [or
46% (six of 13), when not counting the three C®T mutations at
5¢-TpG sites] in PUVA-treated patients and 64% (59/92) in the
Table II. Primers used for PCR-SSCP and sequencing analysis of p53
Exona Primer directionb Primer sequence (5¢®3¢) Length of ampli®ed fragment (BP)
4 F AAT GGA TGA TTT GAT GCT GTC CC 274
R CTC AGG GCA ACT GAC CGT GC
5 F TTC AAC TCT GTC TCC TTC CT 229
R GCC CCA GCT GCT CAC CAT CG
6 F TGG TTG CCC AGG GTC CCC AG 224
R CGG AGG GCC ACT GAC AAC CA
7 F AGG CGC ACT GGC CTC ATC TT 177
R TGT GCA GGG TGG CAA GTG GC
8 F TTC CTT ACT GCC TCT TGC TT 186
R TTG CTT ACC TCG CTT AGT GC
9 F CAA GGG TGC AGT TAT GCC T 161
R ACT TGA TAA GAG GTC CCA A
aPrimers for exons 4 and 5 were selected as described by Brash et al (1991) and for exons 6±9 as described by Wang et al (1997).
bF, forward; R, reverse.
Figure 1 Sequence analysis reveals UV- and
PUVA-type p53 mutations in PUVA-
associated BCC. The upper panel shows
electropherograms of DNA from (A)tumor A4
(exon 5, codon 177), CC®TT transition of UV
type; (B)tumor E3 (exon 7, codon 234), T®C
transition on a potential psoralen binding 5¢-
TpA:ApT site (i.e, of PUVA type); and (C)tumor
A2 (exon 5, codon 155), C®T transition of UV
type. The lower panel shows electropherograms of
wild-type DNA from placenta.
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general population. The difference was deemed not statistically
signi®cant when subjected to Fisher's exact test (p > 0.2);
however, the percentage of p53 mutations at 5¢-TpG sites in
BCC from PUVA-treated patients was statistically signi®cantly
higher than that in the general population [38% (®ve of 13) vs 2%
(two of 92); Fisher's exact test, p < 0.001].
DISCUSSION
In this study, we examined the hypothesis that carcinogen-speci®c
mutations are present in the p53 gene of BCC from PUVA-treated
patients. We found a total of 13 mis-sense or non-sense p53
mutations in seven of 13 BCC (54%) and that 12 of these 13
mutations (92%) were at dipyrimidine sites and that nine (69%) of
the mutations had the UV ®ngerprint (C®T or CC®TT
transitions) (Brash et al, 1991). More important, the percentage of
UV ®ngerprints in PUVA-associated BCC did not signi®cantly
differ from that in the general population (Fig 2). There are several
possible explanations for this high proportion of UV ®ngerprint
p53 mutations. First, most BCC examined were from heavily sun-
exposed body areas; on the other hand no PUVA-associated BCC
from other body sites were available for study. Second, all patients
in this study had a history of UVB treatment (a possible cause of
UV-type p53 mutations). Third, ¯uorescent tubes used for PUVA
therapy in Europe emit a small portion of radiation within the UVB
range (Nataraj et al, 1997), which may in turn cause UV-type
mutations. Fourth, stable oxidation products of cytosine and
thymidine induced by 8-MOP and UVA or by UVA alone could
also induce C®T transitions (Wang et al, 1998). Finally, PUVA
generates reactive oxygen species, which also may induce CC®TT
transitions (Reid and Loeb, 1993). The hypothesis that exposure to
PUVA or UVA alone may result in UV-type mutations, however,
is strongly contradicted by results of cell culture (Sage et al, 1993;
Chiou and Yang, 1995; Gunther et al, 1995) and murine (Nataraj
et al, 1996) studies, in which UV-type mutations were rarely if ever
observed after PUVA exposure.
An important ®nding in this study was that six of the 13 p53
mutations identi®ed (46%) were at potential psoralen-binding sites
and thus may have been induced by PUVA; however, only one
mutation (8%) was at a 5¢-TpA site compared with ®ve (38%) at 5¢-
TpG sites. This ®nding is similar to the results of a previous study
(Nataraj et al, 1997) on PUVA-associated SCC, in which 13 of 25
p53 mutations (52%) were found at 5¢-TpG sites. Although cell
culture (Sage et al, 1993; Chiou and Yang, 1995; Gunther et al,
1995) and murine studies (Nataraj et al, 1996) revealed that 5¢-TpA
sites are the most common targets for PUVA mutagenesis, a cell
culture study (Gunther et al, 1995) using low (clinically relevant)
doses of PUVA revealed that the highest percentage (approximately
one-third) of mutations in murine ®broblasts containing supF DNA
occurred at 5¢-TpG sites. Interestingly, in a study on PUVA-
associated SCC our group of investigators found frequent mutation
of the Ha-ras oncogene and a 28% incidence of mis-sense/non-
sense mutations (®ve of 18) at 5¢-TpG sites (Kreimer-Erlacher et al,
in press). An alternative explanation for PUVA-induced mutations
at 5¢-TpG sites was recently proposed namely, reactive oxygen
species-mediated damage at G, C, and/or T sites (Wang et al, 1998;
Peritz and Gasparro, 1999).
Because molecular epidemiology studies can link mutations to
causative agents, they are a potent tool for determining the factors
that contribute to cancers (Peritz and Gasparro, 1999). In the case
of PUVA-associated skin cancer, however, the situation is made
very complex by the concomitant presence of multiple risk factors
such as exposure to potentially carcinogenic and cocarcinogenic
agents including UVB, X-ray radiation, medical tar, and metho-
trexate (Maier et al, 1996). For instance, two patients in the present
study (C and E) had been exposed in the past to therapeutic arsenic,
a well-known carcinogen that causes skin cancer after long latency
periods. We found two PUVA-type mis-sense mutations (one at a
5¢-TpA site and one at 5¢-TpG site) in the six BCC samples from
those patients but no mutations of any other type; however, arsenic
exposure may lead to G®T transversions via the production of
reactive oxygen species (Shibutani et al, 1991). Interestingly, in
another study, we had found two C®T transitions and one G®T
transversion in the p53 gene of a total of four BCC from two
arsenic-exposed, non-PUVA-treated patients (Seidl et al unpub-
lished results). G®T transversions, however, can also be caused by
exposure to UV-induced singlet oxygen via production of 8-
hydroxyguanosine (Cheng et al, 1992), to benzo[a]pyrenes (e.g,
from tobacco smoke) (Chiba et al, 1990), or to hydrogen radicals
generated by g-radiation (Braun et al, 1993). Patients A, C, and E in
our study all had a history of medical treatment with tar, which may
contain carcinogenic compounds, such as benzo[a]pyrenes
(Godschalk et al, 1998). Indeed, one tumor (A1) harbored at
exon 5 (codon 144) a G®T (G:C®T:A) transversion. Patient A
had also received X-ray radiation on the scalp and oral
Table III. Type of p53 mutations detected in BCC from PUVA-treated psoriasis patients
Tumor Exon Codon Base change Surrounding sequence
Type of
mutationb
Amino acid
change(5¢®3¢)a
A1 4 75 C®T g c c c C t g c a UV Pro®Leu
A1 4 88 C®T c c a g C c c c c UV Ala®Val
A1 4 94 C®T c t g t C a t c t UV/PUVA Ser®Leu
A1 5 144 C®A c a g C t g c a c Other Gln®His
A2 5 155 C®T g g c a c C c g c (UV) None
A2 5 165 C®T a a g C a g t c a PUVA Gln®Stop
A3 4 67 C®T a t g c C a g a g UV/PUVA Pro®Leu
A3 4 82 C®T a c a c C g g c g UV Pro®Leu
A3 4 84 C®T g c g g C c c c t UV Ala®Val
A3 4 88 C®T c c a g C c c c c UV Ala®Val
A3 4 92 C®T t g g c c C c t g (UV) None
A3 5 177 C®T t g c c c C c a c (UV) None
A4 5 177 CC®TT t g c c C C c a c UV Pro®Leu
D1 9 317 C®T c c c C a g c c a UV/PUVA Gln®Stop
E2 7 229 T®A g a c T g t a c c PUVA Cys®Ser
E3 4 122 C®G a g t C a c a g a (PUVA) None
E3 7 234 T®C c a c T a c a a c PUVA Tyr®His
aThe 5-MOP, 5-Methoxypsoralen ¢®3¢ sequence is shown for the strand (transcribed or nontranscribed) containing the pyrimidine(s). Mutated bases are shown in bold.
Multi- and dipyrimidine sequences are underlined. 5¢-TpA:ApT and 5¢-TpG:ApC sequences are double underlined.
bUV-type mutations were de®ned as C®T and CC®TT transitions at dipyrimidines. PUVA-type mutations were de®ned as mutations at potential psoralen-binding sites
5¢-TpA:ApT and 5¢-TpG:ApC. Silent mutations are shown in parenthesis.
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methotrexate for the treatment of psoriasis. It is well-known that
X-ray treatment can cause BCC, possibly by causing G®T
mutations (Braun et al, 1993).
Two BCC (A1 and A3) had multiple mis-sense mutations,
mostly of the UV type (Table III). As sequencing and PCR±SSCP
were carried out on each exon separately and vector cloning was
not performed in our study, it was therefore impossible to
determine whether the mutations in the different exons of the
tumors occurred in the same p53 allele or in different alleles.
Interestingly, in this context, a previous study by Ziegler et al
(1993) revealed that 56% of human BCC contained p53 mutations
and that 45% of the tumors contained a second point mutation on
the other p53 allele. Consistent with the results of our study,
however, D'Errico et al (1997) previously reported that all p53
mutated BCC they studied apparently retained the wild-type p53
allele suggesting that only one p53 allele seems to be inactivated in
BCC. Another previous study found multiple p53 mutations in
eight of 12 PUVA-associated human SCC (Nataraj et al, 1997). In a
study of PUVA-induced SCC in mice, some tumors harbored
multiple p53 mutations (Nataraj et al, 1996). Indeed, the presence
of multiple p53 mutations in cancers suggests that clones harboring
an initial mutation on one allele are targets for a second mutation
on the other allele or that these mutations may arise independently,
perhaps in different clonal subpopulations during tumor develop-
ment (Nataraj et al, 1996). Indeed the latter hypothesis is supported
by our ®nding that some BCC (A2, A3, and E3) had silent
mutations (i.e, no change in amino acid sequence) of the UV or
PUVA type (Table III) and that at least in some cases only a
portion of tumor cells harbored p53 mutations (Fig 1). Clearly, as
was the case with the PUVA-associated SCC studied by Nataraj
et al (1997), not all p53 mutations in tumors may contribute to
tumor development as some mutations may arise after tumor
initiation by repeated exposure to agents such as PUVA and/or
UV(B).
Our present results are also important because they contradict the
previous ®nding of Greenblatt et al (1994) that approximately 90%
of all p53 mutations in cancers occur between exons 5 and 8. In
contrast we found that: (i) seven of 13 p53 mis-sense/non-sense
mutations (54%) occurred in the nonconserved domain of exon 4
(codons 67±94); (ii) three (23%) in the conserved domain III of
exon 5 (codons 144±177); (iii) two (15%) in the conserved domain
IV of exon 7 (codons 229 and 234); and (iv) one (8%) in the
nonconserved domain of exon 9 (codon 317). In previous studies,
pooling of DNA sequencing results revealed that BCC appeared to
have a major mutational hot spot between codons 241 and 280 and
a minor region between codons 161 and 200 (Nataraj et al, 1995;
references cited therein). In this study, we observed two mis-sense
mutations (i.e, C®T transitions at a multipyrimidine site) at codon
88 of exon 4 (tumors A1 and A3), but nowhere else a hotspot mis-
sense mutation incidence on the p53 gene. Mutations in conserved
domains, of the p53 gene have been suggested to destabilize the p53
protein (Cho et al, 1994), but little is known about mutations
outside the conserved core domain.
In conclusion, our study revealed that the majority of p53
mutations in BCC from PUVA-treated patients occurred at
dipyrimidine sites and had the UV ®ngerprint, similar to the case
in the general population (Fig 2); however, a smaller percentage of
the mutations occurred at 5¢-TpG sites, suggesting that even
though the major cause of p53 mutations (and possibly BCC
tumorigenesis) seems to be environmental and/or therapeutic
UV(B) exposure, PUVA itself may directly cause some p53
mutations as well. Moreover, as only about half of the BCC in the
present study harbored p53 mutations, it may be that other tumor
suppressor genes and/or oncogenes are targets for PUVA-associated
damage leading to BCC tumorigenesis. One particular candidate
that needs to be investigated is the ``patched'' gene, which is
frequently mutated in BCC of patients with the basal cell nevus
syndrome and in the general population (reviewed in Wikonkal
and Brash, 1999). This study, however, highlights the value of the
new ®eld of molecular epidemiology as the results con®rm on the
molecular level those of many conventional epidemiologic PUVA
follow-up studies, suggesting that PUVA itself may not be the
major factor in BCC formation in PUVA-treated subjects (Stern
et al, 1998).
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